Copy
NeoStem Announces Closing of $28,750,000 Public Offering of Common Stock
NeoStem Announces Closing of $28,750,000
Public Offering of Common Stock
Over-Allotment Option Exercised


NEW YORK, June 2, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS) ("NeoStem" or the "Company", to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), announced today the closing of a previously announced underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,875,000 additional shares of its common stock bringing the gross proceeds to NeoStem from this offering to $28,750,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. Aegis Capital Corp. acted as sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC) and which became effective on October 3, 2012. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC. Electronic copies of the preliminary prospectus supplement and the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC's website at http://www.sec.gov or from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NeoStem, Inc.
(Soon to be renamed Caladrius Biosciences, Inc. with ticker to be CLBS)

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.

Contact:
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
Please visit our new service www.swiresearch.com. We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.
 
 
 
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site www.stockwatchindex.com, its "Rise Above The Noise" newsletter and SWI Research site www.swiresearch.com. These services provide readers with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on http://www.stockwatchindex.com/swi-quickpicks for more detail.  SWI's periodical "Portfolio Performance Report" frequently reports about the performance of the stocks that we have purchased and may be trading in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.  
 
Facebook
Twitter
LinkedIn
Google +
StockWatchIndex
 
Good luck and please pass this newsletter on to a friend
to continue building our community.
 

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp